Southampton’s Synairgen announces board changes
Synairgen, the Southampton-based biotech company which is set to present findings next month which show that its SNG001 drug reduced the relative risk of recognised symptoms of long Covid compared to placebo, has announced changes to its board.
These will see the appointment of Dr Felicity (‘Flic’) Gabbay to the board as a Non-Executive Director while, simultaneously, Theresa Harold is stepping down from the board, taking effect immediately.
Simon Shaw, Chair of Synairgen, said : "Flic is highly experienced with a deep understanding of drug development and pharmaceutical medicine.
“Over her distinguished career, she has gained invaluable experience in supporting companies to progress their candidate drugs through the clinic and we look forward to benefitting from her insights as we continue the clinical development of SNG001.
“I wish to thank Theo for her contributions during the period of her service and wish her well with her future endeavours."
Read more - mdgroup's LaQuinta Jernigan named one of 100 most inspiring people in life sciences
Flic brings considerable experience in the life sciences sector, having held several senior and CEO positions in pharma, biotech and CROs across Europe and North America.
She has managed drug development work with companies at every stage of the drug development cycle while Founder and Managing Partner of Transcrip LLP, where she also secured private equity investment and the acquisition of Real Regulatory.
Starting her career as a medical doctor, Flic held a number of medical posts around Europe before moving into the biotechnology sector. Currently, she holds the position of President of the Faculty of Pharmaceutical Medicine for the three Royal Colleges of Physicians.
Flic was awarded the Fellowship of the Academy of Medical Science in 2020 and is passionate about bringing pharmaceutical medicine into mainstream medical science and its application to public health.
She completed a BSc in Pharmacology and a Bachelor of Medicine and Surgery degree at the University of Manchester.
Flic Gabbay said: "I am pleased to join the Board of Synairgen as it works towards the next milestones for SNG001 as a potential therapeutic for severe respiratory viral infections.
“I look forward to working closely with the Synairgen Management team and Board on the next steps for the Company's clinical development."
Shares in AIM listed Synairgen dropped 19.8 per cent Thursday (29 September) afternoon.
Read more - Scott Brownrigg to design three life sciences buildings at Oxford Science Park
